RBC Capital analyst Gregory Renza downgraded Verrica Pharmaceuticals (VRCA) to Sector Perform from Outperform with a price target of $2, down from $11. The firm says the company’s “challenging” Q3 of negative net revenues is compounded by a quick CEO transition and strategic review to save Ycanth, manage costs, and restore the balance sheet. RBC sees “an uncertain path” for Verrica and cut its Ycanth forecasts.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica downgraded to Sector Perform from Outperform at RBC Capital
- Verrica Pharmaceuticals: Financial Struggles Amid Strategic Shifts
- Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring
- Verrica Pharmaceuticals reports Q3 EPS (43c), consensus (37c)
- Verrica to preset results on VP-315 at Fall Clinical Dermatology Conference